Autopsy report · NCT04428437

Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors

“The sponsor withdrawed the sponsorship to the study.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 1 month before it started.
• Ran for about 1 year 3 months before it stopped.
• 17 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Humanity & Health Medical Group Limited

Sponsor type

University, hospital or other

Conditions

Hepatocellular Carcinoma

Interventions

Lenvatinib

Participants

17

Sites

1

Countries

Hong Kong

Trials that died the same way

• Serum-Free Thymus Transplantation in DiGeorge Anomaly
  “The sponsor decided to withdraw the study.” (95% match in meaning)
• NRX-1074 in Early Course Schizophrenia
  “The study was withdrawn by the sponsor.” (93% match in meaning)
• Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
  “Sponsor withdrew the study” (92% match in meaning)
• Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
  “Study withdrawn by Sponsor” (88% match in meaning)
• A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants
  “Study was Withdrawn per Sponsor decision.” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.